BioHealth News
CvilleBioHub Enters Into A Virginia Collaboration Network And Will Launch New Biotech Accelerator In Charlottesville
GO Virginia, University of Virginia, Manning Family Foundation, and local Economic Development support the three-year project driving life sciences entrepreneurship. Charlottesville, VA (January 14, 2025) --- The…
Read More
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
ROCKVILLE, Md., Jan. 14, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization…
Read More
EMBL: Researchers uncover what drives aggressive bone cancer
January 14, 2025 - Vicky Hatch - Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the…
Read More
VA Tech Research: Words activate hidden brain processes shaping emotions, decisions, and behavior
In an unprecedented new study in the journal Cell Reports, researchers have shown neurotransmitters in the human brain are released during the processing of the…
Read More
State of Maryland, University of Maryland Announce $1 Billion “Capital of Quantum” Initiative
COLLEGE PARK, Md., January 14, 2025--(BUSINESS WIRE)--IonQ (NYSE: IONQ), a leader in the quantum computing and networking industries, today announced a landmark partnership with…
Read More
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive…
Read More
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet…
Read More
Novavax is Powering the Future of Vaccines Through R&D and Value-creating Business Strategy
January 13, 2025 - By Ruxandra Draghia-Akli, MD, PhD, Executive Vice President, Head of R&D and Elaine O’Hara, Executive Vice President, Chief Strategy Officer As…
Read More
VEDP: Booming Virginia clusters provide a supply chain blueprint for increasing drug accessibility, affordability
Like his fellow Type 1 diabetics, Alec Smith took insulin every day to regulate his blood sugar. Costs to treat his condition topped $1,000…
Read More
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for…
Read More
The Baltimore Banner: University of Maryland merges engineering and medicine to turn ideas into companies
It’s Baltimore’s latest move toward becoming a tech hub Meredith Cohn - 1/11/2025 - It looks like a rolling suitcase, a mask and some tubes, but for…
Read More
ARPA-H RAPID Program: Rare Disease AI/ML for Precision Integrated Diagnostics
*NOTE: Solution Summary due: February 14, 2025The Big Question What if we could end the rare disease diagnostic odyssey? The Problem Collectively, rare diseases…
Read More
Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics
FREDERICK, Md., Jan. 9, 2025 /PRNewswire/ -- Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced today…
Read More
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a…
Read More
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies…
Read More